加载中
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
前收盘价
US$1.33
−US$0.11 · -7.64%
盘中时间采用ET。市场数据可能有所延迟。
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
日内区间
当前US$1.33
52周区间
当前US$1.33
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
56
多空交织
风险
66
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
日内区间
当前US$1.33
52周区间
当前US$1.33
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 373.1万 USD | 762万 USD | 1703.4万 USD | 1632万 USD | 1182.7万 USD |
| 销售、一般及管理费用 | 298.3万 USD | 293.5万 USD | 484.4万 USD | 596.2万 USD | 582.1万 USD |
| 营业费用 | 2745.8万 USD | 1100.5万 USD | 2227.1万 USD | 2260.3万 USD | 1793.4万 USD |
| 利息收入 | 22.7万 USD | 26万 USD | 47.4万 USD | 53.2万 USD | 32万 USD |
| 利息支出 | 3.9万 USD | 4.1万 USD | 5.6万 USD | 6.7万 USD | 7.9万 USD |
| 折旧和摊销 | 20.3万 USD | 18.6万 USD | 19.7万 USD | 20.1万 USD | 23.1万 USD |
| 营业利润 | −2745.8万 USD | −1100.5万 USD | −2227.1万 USD | −2260.3万 USD | −1793.4万 USD |
| 净利润 | −2638.6万 USD | −724万 USD | −1988万 USD | −2166.8万 USD | −1838.4万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
